CASI Pharmaceuticals, Inc. 15,853,658 Shares of Common Stock (par value $0.01 per share) Underwriting AgreementUnderwriting Agreement • March 26th, 2021 • CASI Pharmaceuticals, Inc. • Biological products, (no disgnostic substances) • New York
CASI Pharmaceuticals, Inc., a Delaware corporation (the “Company”), proposes to issue and sell to the several underwriters named in Schedule A (the “Underwriters”) an aggregate of up to 18,231,706 shares of its common stock, par value $0.01 per share (the “Shares”). The 15,853,658 Shares to be sold by the Company are called the “Firm Shares.” In addition, the Company has granted to the Underwriters an option to purchase up to an additional 2,378,048 Shares, which are collectively called the “Option Shares.” The Firm Shares and, if and to the extent such option is exercised, the Option Shares, are collectively called the “Offered Shares.” Oppenheimer & Co. Inc. (“OpCo”) has agreed to act as representative of the several Underwriters (in such capacity, the “Representative”) in connection with the offering and sale of the Offered Shares. To the extent there are no additional underwriters listed on Schedule A, the term “Representative” as used herein shall mean OpCo, as Underwriter, and th
